PRIORITY PARTNERS
7231 Parkway Dr., Suite 100
Hanover, MD 21076

JOHNS HOPKINS
HEALTH PLANS

10/17/2025

Prior Authorization

Internal Use Only

JOHNS HOPKINS HEALTH PLANS
Aqneursa - Priority Partners MCO

This fax machine is located in a secure location as required by HIPAA regulations.
Complete/review information, sign and date. Fax signed forms to Johns Hopkins Health Plans at **1-410-424-4607**.
Please contact Johns Hopkins Health Plans at **1-888-819-1043** with questions regarding the Prior Authorization process.
When conditions are met, we will authorize the coverage of Aqneursa - Priority Partners MCO.

Drug Name (select from list of drugs shown)
Aqneursa (levacetylleucine)

Quantity Frequency Strength

Route of Administration Expected Length of Therapy

Patient Information
Patient Name: _____
Patient ID: _____
Patient Group No.: _____
Patient DOB: _____
Patient Phone:

Prescribing Physician
Physician Name: _____
Physician Phone: _____
Physician Fax: _____
Physician Address: _____
City, State, Zip: _____

Diagnosis: _____ **ICD Code:** _____

Comments: _____

Please circle the appropriate answer for each question.

1. Will the requested medication be used for any indications that are not Food and Drug Administration (FDA)-approved or guideline-supported? Y N

[If yes, no further questions.]

2.	Will the requested medication be used concurrently with Miplyffa (arimoclomol)?	Y N
	[If yes, no further questions.]	
3.	Has the plan authorized this medication in the past for this patient (i.e., previous authorization is on file under this plan)?	Y N
	NOTE: The use of physician samples, or manufacturer product discounts, does not guarantee coverage under the provisions of the medical and/or pharmacy benefit. All pertinent criteria must be met in order to be eligible for benefit coverage.	
	[If no, skip to question 5.]	
4.	Is there documentation demonstrating patient has experienced a positive clinical response, evidenced by stabilization, slowed progression, or improvement in Niemann-Pick disease type C (NPC) symptoms from baseline (motor function, swallowing, and speech/cognitive features) supported by a change in functional Scale for Assessment and Rating of Ataxia (fSARA) score?	Y N
	NOTE: Submission of medical records is required.	
	[No further questions.]	
5.	Has the documentation been submitted showing a diagnosis of Niemann-Pick disease type C (NPC), confirmed by genetic testing showing biallelic pathogenic variants in either the NPC1 or NPC2 gene?	Y N
	NOTE: Submission of medical records is required.	
	[If no, no further questions.]	
6.	Has documentation been submitted showing the patient has had one or more neurological manifestations of NPC, such as loss of motor function, swallowing, or speech and cognitive impairment?	Y N
	NOTE: Submission of medical records is required.	
	[If no, no further questions.]	
7.	Has documentation been submitted showing the patient has had a baseline score on the functional Scale for Assessment and Rating of Ataxia (fSARA)?	Y N
	NOTE: Submission of medical records is required.	
	[If no, no further questions.]	
8.	Is the patient 4 years of age or older?	Y N
	[If no, no further questions.]	
9.	Does the patient weigh 15 kilograms (33 lbs) or greater?	Y N
	NOTE: Submission of medical records is required.	

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is

available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date